Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib hepatic impairment pharmacokinetic study in advanced solid tumors
NL-OMON45128Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in Nonhematologic neoplasms (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration of olaparib, Time to maximum plasma concentration of olaparib and 6 more. Started Mar 2014; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON45128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45128.